Kiniksa Pharmaceuticals Ltd Cash Flow Quality Index
Kiniksa Pharmaceuticals Ltd cash flow quality index. Kiniksa Pharmaceuticals Ltd (KNSA) has a Cash Flow Quality Index of 1.87x as of June 2026. Operating cash flow of $47.46 Million exceeds net income of $25.43 Million, indicating high earnings quality where cash backs reported profits. See Kiniksa Pharmaceuticals Ltd leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Kiniksa Pharmaceuticals Ltd (2022–2023)
Cash flow quality index of Kiniksa Pharmaceuticals Ltd from 2022 to 2023. Historical Cash Flow Quality Index for Kiniksa Pharmaceuticals Ltd across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore KNSA operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Kiniksa Pharmaceuticals Ltd Cash Flow Quality Index by Year (2022–2023)
Kiniksa Pharmaceuticals Ltd cash flow quality index by year from 2022 to 2023. Year-by-year earnings quality comparison for Kiniksa Pharmaceuticals Ltd. For the full cash flow conversion analysis, see KNSA cash flow metrics.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2023 | 0.94x | $13.30 Million | $14.08 Million | ▲ +2882.1% |
| 2022 | 0.03x | $5.81 Million | $183.36 Million | — |